CHANGES IN SECRETORY PATHWAY MARKERS IN A PC12 CELL MODEL OF PARKINSON´S DISEASE

SAMPIERI, L; TORRES DEMICHELIS, VA; DI GIUSTO, P; ALVAREZ, C

Córdoba

Congreso; SAIB 2016; 2016

CB-P05 CHANGES IN SECRETORY PATHWAY MARKERS IN A PC12 CELL MODEL OF PARKINSON´S DISEASE Sampieri L, Torres Demichelis VA, Di Giusto P, Alvarez C.  CIBICI-CONICET. Fac. de Cs. Qcas. Universidad Nacional de Córdoba.E-mail: lsampieri@fcq.unc.edu.ar The secretory pathway must adapt to physiological situations like cell differentiation. There is little known about this adaptation process, as well as the connection between membrane trafficking and neurodegeneration. We aim to elucidate biochemical and morphological changes involving the secretory pathway that occur in Nerve Growth Factor (NGF) differentiated PC12 cells and in these cells treated with an analogue of Dopamine, 6-Hydroxy Dopamine (6-OHDA); a model of Parkinson´s Disease (PD). We found that NGF induces a time-dependent increase in protein levels of ER-Golgi markers, while their mRNA levels do not seem to vary. In contrast, transcript levels of endocytic pathway markers increase. We showed that increase in transport proteins due to 6-OHDA treatment is higher than that caused by NGF and that the Golgi is disrupted. Curiously, we did not detect a significant increase in the levels of α-synuclein, a well known marker of PD. This suggests that, in this model, 6-OHDA toxicity may not be mediated by αsynuclein. Taken together, our data suggest that: a) the regulation of the secretory pathway in differentiating PC12 cells may occur via post-translational modifications and b) the changes in transport factors levels due to 6-OHDA could happen to overcome Golgi fragmentation. We aim to investigate the molecular mechanisms underlying this response in different conditions.